Skip to content

Alkermes ALKS Additional Paid-In Capital

Additional Paid-In Capital at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
AbbVie logo
AbbVieABBV
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's additional paid-in capital?
Alkermes (ALKS) reported additional paid-in capital of $3.06B in Q1 2026.
How has Alkermes's additional paid-in capital changed year-over-year?
Alkermes's additional paid-in capital increased by 4.9% year-over-year, from $2.91B to $3.06B.
What is the long-term trend for Alkermes's additional paid-in capital?
Over 5 years (2020 to 2025), Alkermes's additional paid-in capital has grown at a 2.3% compound annual growth rate (CAGR), from $2.69B to $3B.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.